Preliminary Efficacy, Safety Identified for Treatment Option for Patients With Multiple Myeloma

Alfred L Garfall, MD, MS, assistant professor of Medicine, Perelman School of Medicine, University of Pennsylvania, discusses his recent study presented at ASH 2020, which examined the use of teclistamab for the treatment of multiple myeloma, highlighting a manageable safety profile, including low severe infection and neurotoxicity rates. 

Reference:

Garfall A, Usmani S, Mateos MV, et al. Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM) (Abstract 180). https://ash.confex.com/ash/2020/webprogram/Paper138831.html. December 5, 2020.